Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Novocure (NVCR) recognized first non-small cell lung cancer revenues ahead of schedule, with 92 Optune Lua prescriptions for NSCLC received in ...

Discover NovoCure's Q1 2025 earnings insights, including Optune Lua's NSCLC progress, global market growth, and strong revenue performance.

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective.

Merck , known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. "Our company made strong progress to start the year, with increasing ...